Plus more appointments in contract pharma in this week's column.
Ergomed, a British drug development services company, has appointed Rolf Stahel to its board as a non-executive Chairman. Stahel was also recently made non-executive Chairman of Midatech , a UK company which uses gold nanoparticles for drug delivery.
The pharmaceutical veteran was CEO of Shire between 1994 and 2003, a tenure during which he oversaw six mergers and acquisitions. Prior to this, he worked for 27 years at Wellcome, where he rose to Director of Group Marketing, covering R&D portfolio decisions. Stahel also sits on the advisory board of Imperial Business School at Imperial College, London.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions